Ilomedin in Septic Shock With Persistent Microperfusion Defects (I-MICRO)
Status:
Recruiting
Trial end date:
2022-08-18
Target enrollment:
Participant gender:
Summary
Septic shock remains a major cause of death in critically ill patients. Alterations in
microcirculation have long been proposed as a key pathophysiological factor of organ
dysfunction and death in septic shock patients. Persistence of mottling, prolonged skin
recoloration time and cyanosis of the extremities are the easily and frequently observed
manifestations of these microcirculatory disorders. Ilomedin is a prostaglandin analog with a
potent vasodilatory effect together with anti-thrombotic properties (inhibition of platelet
aggregation) preferentially at the microcirculatory level. An increase in cardiac output with
increased arterial oxygen delivery has been observed in clinical and preclinical studies with
no episodes of hypotension. Improvement in mesenteric perfusion has moreover been observed in
experimental sepsis using Ilomedin. Our group has furthermore reported that administration of
Ilomedin in patients with refractory septic shock (peripheral hypoperfusion) resulted in a
rapid and sustained improvement in peripheral perfusion. Altogether, Ilomedin may prevent or
improve recovery of organ dysfunction in septic shock patients through recruitment of the
microcirculation and, thereby, ultimately improve outcome.